Top 5 Stock Picks of Samuel Isaly’s OrbiMed Advisors

2. Prelude Therapeutics Incorporated (NASDAQ:PRLD)

OrbiMed Advisors Stake Value: $313,740,000
Percentage of OrbiMed Advisors’ 13F Portfolio: 3.44%
Number of Hedge Fund Holders: 7

Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a biopharmaceutical business in the United States. Baker Bros. Advisors, with approximately 10.12 million shares worth $316.37 million, is the largest shareholder of Prelude Therapeutics Incorporated (NASDAQ:PRLD) as of Q3 2021.

Prelude Therapeutics Incorporated (NASDAQ:PRLD)’s price objective was trimmed to $20 from $33 in November by Barclays analyst Peter Lawson, who maintained an “Overweight” rating on the stock. In anticipation of more information on the company’s management changes, the analyst decreased the price target.

At the end of the third quarter of 2021, 7 hedge funds in the database of Insider Monkey held stakes worth $851.40 million in Prelude Therapeutics Incorporated (NASDAQ:PRLD), up from 6 funds in the preceding quarter, holding stakes in the company worth $866.87 million.